Christian Munk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Christian Munk has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Susanne Kriiger Kjaer
Unit of Virus, Lifestyle and Genes Danish Cancer Institute Copenhagen Denmark
18 shared publications - David E. Gloriam
Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark
7 shared publications - Bo Terning Hansen
Norwegian Institute of Public Health, Oslo, Norway
6 shared publications - Kai-Li Liaw
Merck & Co, Inc, Rahway, NJ, United States
6 shared publications - Mari Nygård
Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health , Oslo
6 shared publications - Kasper Harpsøe
University of Copenhagen
5 shared publications
Latest Publications
- 16 February 2026
- Published by Elsevier in Preventive Medicine
- Vol. 206, 108541
A 20-year study of incidence trends of anogenital warts in Denmark –population impact of human papillomavirus vaccination
- 16 February 2026
- Published by Elsevier in Preventive Medicine
- Vol. 206, 108541
A 20-year study of incidence trends of anogenital warts in Denmark –population impact of human papillomavirus vaccination
- Open Access
- 10 November 2021
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 28 (11) , 875-878
An online GPCR structure analysis platform
We present an online, interactive platform for comparative analysis of all available G-protein coupled receptor (GPCR) structures while correlating to functional data. The comprehensive platform encompasses structure similarity, secondary structure, protein backbone packing and movement, residue–residue contact networks, amino acid properties and prospective design of experimental mutagenesis studies. This lets any researcher tap the potential of sophisticated structural analyses enabling a plethora of basic and applied receptor research studies.
- 10 November 2021
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 28 (11) , 875-878
Open AccessAn online GPCR structure analysis platform
We present an online, interactive platform for comparative analysis of all available G-protein coupled receptor (GPCR) structures while correlating to functional data. The comprehensive platform encompasses structure similarity, secondary structure, protein backbone packing and movement, residue–residue contact networks, amino acid properties and prospective design of experimental mutagenesis studies. This lets any researcher tap the potential of sophisticated structural analyses enabling a plethora of basic and applied receptor research studies.
- 1 May 2020
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 92, 105996
Use of real-world data for HPV vaccine trial follow-up in the Nordic region
- 1 May 2020
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 92, 105996
Use of real-world data for HPV vaccine trial follow-up in the Nordic region
- 1 February 2020
- Published by Elsevier in Preventive Medicine
- Vol. 131, 105944
Factors associated with condom use during sexual intercourse with a new partner among Scandinavian women
- 1 February 2020
- Published by Elsevier in Preventive Medicine
- Vol. 131, 105944
Factors associated with condom use during sexual intercourse with a new partner among Scandinavian women
- Open Access
- 19 December 2019
- Published by Wiley in Cancer Medicine
- Vol. 9 (3) , 1058-1068
Methylation of CpG 5962 in L1 of the human papillomavirus 16 genome as a potential predictive marker for viral persistence: A prospective large cohort study using cervical swab samples
Several studies have demonstrated that the viral genome can be methylated by the host cell during progression from persistent infection to cervical cancer. The aim of this study was to investigate whether methylation at a specific site could predict the development of viral persistence and whether viral load shows a correlation with specific methylation patterns. HPV16‐positive samples from women aged 20–29 years (n = 99) with a follow‐up time of 13 years, were included from a Danish cohort comprising 11 088 women. Viral load was measured by real‐time PCR and methylation status was determined for 39 CpG sites in the upstream regulatory region (URR), E6/E7, and L1 region of HPV16 by next‐generation sequencing. Participants were divided into two groups according to whether they were persistently (≥ 24 months) or transiently HPV16 infected. The general methylation status was significantly different between women with a persistent and women with a transient infection outcome (P = .025). One site located in L1 (nt. 5962) was statistically significantly (P = .00048) different in the methylation status after correction using the Holm‐Sidak method (alpha = 0.05). Correlation analyses of samples from HPV16 persistently infected women suggest that methylation is higher although viral load is lower. This study indicates that methylation at position 5962 of the HPV16 genome within the L1 gene might be a predictive marker for the development of a persistent HPV16 infection.
- 19 December 2019
- Published by Wiley in Cancer Medicine
- Vol. 9 (3) , 1058-1068
Open AccessMethylation of CpG 5962 in L1 of the human papillomavirus 16 genome as a potential predictive marker for viral persistence: A prospective large cohort study using cervical swab samples
Several studies have demonstrated that the viral genome can be methylated by the host cell during progression from persistent infection to cervical cancer. The aim of this study was to investigate whether methylation at a specific site could predict the development of viral persistence and whether viral load shows a correlation with specific methylation patterns. HPV16‐positive samples from women aged 20–29 years (n = 99) with a follow‐up time of 13 years, were included from a Danish cohort comprising 11 088 women. Viral load was measured by real‐time PCR and methylation status was determined for 39 CpG sites in the upstream regulatory region (URR), E6/E7, and L1 region of HPV16 by next‐generation sequencing. Participants were divided into two groups according to whether they were persistently (≥ 24 months) or transiently HPV16 infected. The general methylation status was significantly different between women with a persistent and women with a transient infection outcome (P = .025). One site located in L1 (nt. 5962) was statistically significantly (P = .00048) different in the methylation status after correction using the Holm‐Sidak method (alpha = 0.05). Correlation analyses of samples from HPV16 persistently infected women suggest that methylation is higher although viral load is lower. This study indicates that methylation at position 5962 of the HPV16 genome within the L1 gene might be a predictive marker for the development of a persistent HPV16 infection.
- 1 April 2019
- Published by Elsevier in Contraception
- Vol. 99 (4) , 217-221
Contraceptive use at first intercourse is associated with subsequent sexual behaviors
- 1 April 2019
- Published by Elsevier in Contraception
- Vol. 99 (4) , 217-221
Contraceptive use at first intercourse is associated with subsequent sexual behaviors
- 21 January 2019
- Published by Springer Nature in Nature Methods
- Vol. 16 (2) , 151-162
An online resource for GPCR structure determination and analysis
G-protein-coupled receptors (GPCRs) transduce physiological and sensory stimuli into appropriate cellular responses and mediate the actions of one-third of drugs. GPCR structural studies have revealed the general bases of receptor activation, signaling, drug action and allosteric modulation, but so far cover only 13% of nonolfactory receptors. We broadly surveyed the receptor modifications/engineering and methods used to produce all available GPCR crystal and cryo-electron microscopy (cryo-EM) structures, and present an interactive resource integrated in GPCRdb (http://www.gpcrdb.org) to assist users in designing constructs and browsing appropriate experimental conditions for structure studies.
- 21 January 2019
- Published by Springer Nature in Nature Methods
- Vol. 16 (2) , 151-162
An online resource for GPCR structure determination and analysis
G-protein-coupled receptors (GPCRs) transduce physiological and sensory stimuli into appropriate cellular responses and mediate the actions of one-third of drugs. GPCR structural studies have revealed the general bases of receptor activation, signaling, drug action and allosteric modulation, but so far cover only 13% of nonolfactory receptors. We broadly surveyed the receptor modifications/engineering and methods used to produce all available GPCR crystal and cryo-electron microscopy (cryo-EM) structures, and present an interactive resource integrated in GPCRdb (http://www.gpcrdb.org) to assist users in designing constructs and browsing appropriate experimental conditions for structure studies.
- Open Access
- 11 January 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (2) , 839-849
Human papillomavirus types in cervical high‐grade lesions or cancer among Nordic women—Potential for prevention
It is valuable to establish a population‐based prevaccination baseline distribution of human papillomavirus (HPV) types among women with high‐grade cervical intraepithelial neoplasia (CIN) grade 2 or 3 and cervical cancer in order to assess the potential impact of HPV vaccination. In four countries (Denmark, Norway, Sweden, and Iceland), we collected consecutive series of cervical cancers (n = 639) and high‐grade precancerous cervical lesions (n = 1240) during 2004‐2006 before implementation of HPV vaccination and subjected the specimens to standardized HPV genotyping. The HPV prevalence was 82.7% (95% confidence interval [CI] 79.0‐86.4) in CIN2, 91.6% (95% CI 89.7‐93.5) in CIN3, and 86.4% (95% CI 83.7‐89.1) in cervical cancer. The most common HPV types in CIN2/3 were HPV16 (CIN2: 35.9%, 95% CI 31.2‐40.6; CIN3: 50.2%, 95% CI 46.8‐53.6) and HPV31 (CIN2: 10.9%, 95% CI 7.8‐13.9; CIN3: 12.1%, 95% CI 9.9‐14.3), while HPV16 and HPV18 were the most frequent types in cervical cancer (48.8%, 95% CI 44.9‐52.7 and 15.3%, 95% CI 12.5‐18.1, respectively). The prevalence of HPV16/18 decreased with increasing age at diagnosis in both CIN2/3 and cervical cancer (P < 0.0001). Elimination of HPV16/18 by vaccination is predicted to prevent 42% (95% CI 37.0‐46.7) of CIN2, 57% (95% CI 53.8‐60.5) of CIN3 and 64% (95% CI 60.3‐67.7) of cervical cancer. Prevention of the five additional HPV types HPV31/33/45/52/58 would increase the protection to 68% (95% CI 63.0‐72.2) in CIN2, 85% (95% CI 82.4‐87.2) in CIN3 and 80% (95% CI 77.0‐83.2) in cervical cancer. This study provides large‐scale and representative baselines for assessing and evaluating the population‐based preventive impact of HPV vaccination.
- 11 January 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (2) , 839-849
Open AccessHuman papillomavirus types in cervical high‐grade lesions or cancer among Nordic women—Potential for prevention
It is valuable to establish a population‐based prevaccination baseline distribution of human papillomavirus (HPV) types among women with high‐grade cervical intraepithelial neoplasia (CIN) grade 2 or 3 and cervical cancer in order to assess the potential impact of HPV vaccination. In four countries (Denmark, Norway, Sweden, and Iceland), we collected consecutive series of cervical cancers (n = 639) and high‐grade precancerous cervical lesions (n = 1240) during 2004‐2006 before implementation of HPV vaccination and subjected the specimens to standardized HPV genotyping. The HPV prevalence was 82.7% (95% confidence interval [CI] 79.0‐86.4) in CIN2, 91.6% (95% CI 89.7‐93.5) in CIN3, and 86.4% (95% CI 83.7‐89.1) in cervical cancer. The most common HPV types in CIN2/3 were HPV16 (CIN2: 35.9%, 95% CI 31.2‐40.6; CIN3: 50.2%, 95% CI 46.8‐53.6) and HPV31 (CIN2: 10.9%, 95% CI 7.8‐13.9; CIN3: 12.1%, 95% CI 9.9‐14.3), while HPV16 and HPV18 were the most frequent types in cervical cancer (48.8%, 95% CI 44.9‐52.7 and 15.3%, 95% CI 12.5‐18.1, respectively). The prevalence of HPV16/18 decreased with increasing age at diagnosis in both CIN2/3 and cervical cancer (P < 0.0001). Elimination of HPV16/18 by vaccination is predicted to prevent 42% (95% CI 37.0‐46.7) of CIN2, 57% (95% CI 53.8‐60.5) of CIN3 and 64% (95% CI 60.3‐67.7) of cervical cancer. Prevention of the five additional HPV types HPV31/33/45/52/58 would increase the protection to 68% (95% CI 63.0‐72.2) in CIN2, 85% (95% CI 82.4‐87.2) in CIN3 and 80% (95% CI 77.0‐83.2) in cervical cancer. This study provides large‐scale and representative baselines for assessing and evaluating the population‐based preventive impact of HPV vaccination.
- 24 September 2018
- Published by Wiley in International Journal of Cancer
- Vol. 144 (8) , 1975-1982
Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types
Human papillomavirus (HPV) is essential in cervical carcinogenesis, however, less is known about the carcinogenic potential of individual HPV types. Our aim was to examine the risk of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) after persistence of 13 individual oncogenic HPV types. Liquid‐based cervical samples (n = 40,399) collected in 2002–2005 were tested for HPV by hybrid capture 2 and genotyped with INNO‐LiPAv2. Persistence was defined as having the same genotype twice 1–4.5 years apart. The absolute risk of CIN3+ was estimated by the Aalen‐Johansen estimator and Cox proportional hazard regression was used to compare the rates of CIN3+ according to HPV type adjusting for age and time between HPV tests. Of 2,875 oncogenic HPV‐positive women, 874 had persistence of one or more types and 761 persisted for one oncogenic HPV type only. Persistent HPV16 infection was associated with the highest risk of CIN3+, with an 8‐year absolute risk of 55% (95% CI: 45%–66%), followed by HPV33 (33% (95% CI: 20%–50%)), HPV18 (32% (95% CI: 20%–48%)) and HPV31 (31% (95% CI: 21%–46%)). Other HPV types, including HPV52 and HPV45, were also associated with high risks. Persistent HPV56 had the lowest 8‐year absolute risk of CIN3+ (3% (95% CI: 0.4%–20%)). In Cox analyses, a similar pattern remained after adjustment for age and time between tests. Our results add knowledge about the varying carcinogenic potential of individual persistent oncogenic HPV types, which may have implications for the clinical use of HPV testing.
- 24 September 2018
- Published by Wiley in International Journal of Cancer
- Vol. 144 (8) , 1975-1982
Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types
Human papillomavirus (HPV) is essential in cervical carcinogenesis, however, less is known about the carcinogenic potential of individual HPV types. Our aim was to examine the risk of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) after persistence of 13 individual oncogenic HPV types. Liquid‐based cervical samples (n = 40,399) collected in 2002–2005 were tested for HPV by hybrid capture 2 and genotyped with INNO‐LiPAv2. Persistence was defined as having the same genotype twice 1–4.5 years apart. The absolute risk of CIN3+ was estimated by the Aalen‐Johansen estimator and Cox proportional hazard regression was used to compare the rates of CIN3+ according to HPV type adjusting for age and time between HPV tests. Of 2,875 oncogenic HPV‐positive women, 874 had persistence of one or more types and 761 persisted for one oncogenic HPV type only. Persistent HPV16 infection was associated with the highest risk of CIN3+, with an 8‐year absolute risk of 55% (95% CI: 45%–66%), followed by HPV33 (33% (95% CI: 20%–50%)), HPV18 (32% (95% CI: 20%–48%)) and HPV31 (31% (95% CI: 21%–46%)). Other HPV types, including HPV52 and HPV45, were also associated with high risks. Persistent HPV56 had the lowest 8‐year absolute risk of CIN3+ (3% (95% CI: 0.4%–20%)). In Cox analyses, a similar pattern remained after adjustment for age and time between tests. Our results add knowledge about the varying carcinogenic potential of individual persistent oncogenic HPV types, which may have implications for the clinical use of HPV testing.